ENMD-1068 HCl

Research use only, not for human use.

ENMD-1068 is a PAR-2 antagonist. ENMD-1068 inhibits the development of endometriosis in a mouse model.

ENMD-1068 is a PAR-2 antagonist. ENMD-1068 inhibits the development of endometriosis in a mouse model.

Western Blot Analysis Cell Line:Hepatic stellate cells (HSCs) (TGF-β1-stimulated)Concentration:10 mM Incubation Time:24 h Result:Inhibited TGF-β1-induced expression of α-SMA, Col α1(?),Col α1(III), and Smad2/3 C-terminal phosphorylation.

Animal Model:ICR mice (8-week-old; CCl4-induced liver fibrosis model).Dosage:25, 50 mg/kg Administration:Intraperitoneal injection; twice per week for 4 weeks Result:Markedly attenuated collagen deposition.Animal Model:Mice with surgically induced endometriosis.Dosage:25, 50 mg/kg Administration:Intraperitoneal injection; single daily for 5 days Result:Reduced the volume of observed lesions in a dose-dependent manner.Inhibited the expression of IL-6 and MCP-1.Decreased the proliferation rate of endometriotic cells and increased the percentage of apoptotic epithelial cells in the lesions.

ENMD1068 | ENMD-1068 | ENMD 1068 | ENMD-1068 HCl | ENMD-1068 hydrochloride

Proteasome/Ubiquitin

Serine Protease

PEGs

——

——

789488-77-3

319.87

C15H30ClN3O2

>98% (HPLC)

——

Cl.CC(C)CC(=O)N1CCN(CC1)C(=O)CCCCCN

——

(-20℃)

With Ice Pack

≥ 2 years